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63 ABSTRACT: Recent research has demonstrated that all
64 body ﬂuids assessed contain substantial amounts of vesicles
65 that range in size from 30 to 1000 nm and that are
66 surrounded by phospholipid membranes containing diﬀer-
67 ent membrane microdomains such as lipid rafts and
68 caveolae. The most prominent representatives of these
69 so-called extracellular vesicles (EVs) are nanosized exo-
70 somes (70−150 nm), which are derivatives of the endosomal
71 system, and microvesicles (100−1000 nm), which are
72 produced by outward budding of the plasma membrane.
73 Nanosized EVs are released by almost all cell types and
74 mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-
75 speciﬁc signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical
76 functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative
77 medicine, and drug delivery. Undoubtedly, the rapidly emerging ﬁeld of basic and applied EV research will signiﬁcantly
78 inﬂuence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical,
79 academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST)
80 program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential
81 of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
82Strategic platforms for nanomedicine seek to exploit the83 improved (and often novel) physical, chemical, and84 biological properties of nanomaterials. However, these
85 documents specify that there is an urgent need for bio-
86 mimetism, namely, the process of simulating what occurs in
87 nature.1−3
88 Extracellular vesicles (EVs), such as exosomes and small
89 microvesicles, are nanovesicles, naturally released from cells in
90 both normal or diseased states. Reﬂecting their cells of origin,
91 these EVs are assembled by speciﬁc sets of molecules including
92 proteins, lipids, metabolites, and nucleic acids. According to
93 their molecular signature, they are able to interact speciﬁcally
94 with selected target cells at local or distant sites, within or
95 between organs.4 Considered to be a vectorized signaling
96 system, they seem to bind to speciﬁc membrane microdomains
97 on their target cells; among others, these membrane micro-
98 domains contain transmembrane receptors, integrins, and cell-
99adhesion molecules. To transmit their information, they either
100fuse with the plasma membrane or get incorporated by
101endocytotic processes (Figure 1). Thus, in addition to direct
102cell−cell contact and soluble factors (e.g., cytokines, chemo-
103kines, and hormones), EV-mediated signaling provides a third
104complex and targeted mode of intercellular communication.5
105According to their features, EVs are ideal candidates to serve
106as biomarkers, nanosized drug-delivery vehicles, and mediators
107for a variety of therapeutics in oncology, immune therapy, and
108regenerative medicine.4,6 Thus, EVs have the potential for great
109clinical impact in nanomedicine. The dual potential of EVs
110as diagnostic tools and as therapeutic agents supports their
111use in “theranostics”. This area of nanomedicine focuses on
112multidisciplinary research to set up new systems for various
113nanobiomedical applications, ranging from the medical use of
114nanoplatform-based diagnostic agents, to therapeutic agents,
115to possible future applications of diagnosis and therapy.7
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116 Theranostics includes the early detection of diseases, the
117 monitoring of therapeutic responses, and the targeted delivery
118 of therapeutic agents. Theranostics at the nanoscale encom-
119 passes nanoprobes, nanocarriers, and nanodiagnostics. How-
120 ever, the most important task of a theranostic strategy concerns
121 theranostic nanoformulations, which deal with the develop-
122 ment of new agents based on a “whole-in-one approach”, which
123 should have maximal application in the ﬁeld of personalized
124 medicine. Extracellular vesicles appear to be ideal nanovectors
125 for theranostics, with maximal potential for targeting the
126 disease site with only minimal side eﬀects. If successful, the
127 proof-of-concept in the use of EVs as autologous or allogeneic
128 nanovectors for both diagnosis and therapy of major diseases
129 will enable widespread preclinical and clinical applications.
130 NANOSIZED EXTRACELLULAR VESICLES AS DISEASE
131 BIOMARKERS
132 In this section, we present data supporting the future of
133 nanosized EVs as potentially the most reliable biomarkers in
134 medicine. The majority of the available clinical data have been
135 obtained from studies of cancer patients. However, based on
136 the more limited data emerging from studies of other patho-
137 logies, the ensemble of the data supports EVs found in bodily
138 ﬂuids as a source of biomarkers for all human diseases evaluated
139 thus far. The current “equipment” of disease biomarkers
140 represents an unmet clinical need, and so far, many approaches
141 have searched for single molecules as biomarkers. As an example,
142 prostate-speciﬁc antigen (PSA) is a prominent molecule that is
143 used as a prostate cancer (PCa) marker. Plasma PSA
144 determination is now used worldwide in PCa screening, and it
145 rapidly replaced digital rectal examination for early detection of
146 cancer.8,9 Plasma PSA is controversial as a PCa biomarker,
147 however,10−12 due to the likelihood of false positives, including
148 benign prostatic hyperplasia (BPH).11 Since PSA testing fails to
149 discriminate between BPH and tumors, the use of this analysis
150 causes overdiagnosis and overtreatment with consequent patients
151 suﬀering side eﬀects.11,13−15 Prostate-speciﬁc antigen values
152above 4.0 ng per milliliter are considered abnormal; however,
153cutoﬀ levels can change with age, race, and individual
154physiological condition,11,13,14 with no signiﬁcant progress in
155the last decades.16 As multimolecular aggregates, EVs oﬀer the
156unique opportunity to use a combination of diﬀerent markers
157speciﬁcally expressed on tumor-derived EVs. In fact, serum PSA
158has been detected on plasma and urine- derived EVs in a large
159 pclinical study.17,18
160Tumors. Tumor-derived EVs are proposed to contain a
161tumor-speciﬁc molecular signature, qualifying them as potential
162biomarkers in tumor diagnostics.19 Such EVs can be harvested
163from bioﬂuids such as blood and, for some cancer types, urine.
164In addition to PSA, clinical studies on other EV-associated
165cancer biomarkers have already been described and are
166summarized in Table 1. For example, a retrospective study
167on EV-associated biomarkers in stages III and IV melanoma
168patients showed increased levels of plasmatic caveolin-1 and
169CD63-positive EVs.20 Researchers found that EV-associated
170caveolin-1 displayed a sensitivity of 69% and speciﬁcity of
17196.3%, whereas a conventional cancer biomarker used in the
172follow up of melanoma patients, such as lactate dehydrogenase
173(LDH) serum levels, was altered in only 12.5% of patients.20
174More recently, a study in patients with pancreatic cancer found
175that glypican-1 (GPC1)-positive EVs were detectable in the
176serum of patients with pancreatic cancer with high levels of
177speciﬁcity and sensitivity and could distinguish healthy subjects
178and patients with a benign pancreatic disease from patients with
179early- and late-stage pancreatic cancer.21 Moreover, breast cancer
180patients also presented high levels of GPC1 on EVs, suggesting
181that an increase of certain EV subtypes might represent a hall-
182mark of malignant cancers in general. In fact, EV concentration
183could also be used as an indicator of clinical status. For example,
184when the eﬀect of treatment with imatinib due to a
Figure 1. Exosomes, a natural source of nanoparticles to target cell membranes and deliver bioactive molecules or to be analyzed for
biomarkers. (A) Extracellular vesicles are 50−300 nm vesicles surrounded by a lipid bilayer. Such physical characteristics are uniquely observed
by cryo-electron microscopy (exempliﬁed by a picture of exosomes derived from a human melanocytic cell line observed by cryo-EM. Credit:
G. van Niel and A. Di Cicco. (B) Schematic representation of extracellular vesicles and the potential bioactive molecules and biomarkers that
can be associated. Families of molecules of interest are classiﬁed by color codes as detailed in the text beneath. Credit: G. van Niel.
EVs have the potential for great clinical
impact in nanomedicine.
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185 gastrointestinal stromal tumor was monitored, researchers found
186 that the concentration of EVs before the treatment was increased
187 with respect to the control.22 Elevated levels of EV-expressing
188 TYRP-2, VLA- 4, HSP70, and HSP90 have been detected in the
189 plasma of melanoma patients.23 Both HSP70 and HSP90 belong
190 to the family of heat shock proteins (HSPs), which may emerge
191 as a novel class of EV-associated cancer biomarkers.19
192 Remarkably, EV-associated levels of HSP60 were dramatically
193 decreased in colon cancer patients after surgical removal of
194 the tumor.24 As previously mentioned, EVs may also shuttle
195 well-known tumor markers such as PSA. The EV-associated
196biomarker survivin has also been identiﬁed as a promising
197surrogate biomarker for early diagnosis of PCa.25 Furthermore,
198in PCa patients, the EV concentration, as measured by nano-
199particle tracking analysis (NTA), is higher than that in the
200plasma of healthy controls.26 Interesting results were obtained by
201comparing N-glycan proﬁles of EVs from indolent and aggressive
202prostate cancer to those from noncancerous proﬁles.27 Other
203series of clinical data of paramount importance are summarized
204in Table 1.
205Interestingly, in addition to plasma and serum bioﬂuids, other
206bioﬂuids may represent valuable sources of EV biomarkers.
Table 1. Clinical Data Showing the Role of Nanosized Extracellular Vesicles as Tumor Biomarkers
cancer biomarker indication bioﬂuid clinical study size ref
PSA prostate cancer screening/early
diagnosis
urine controls N = 10; disease N = 24 17
PSA prostate cancer screening/early
diagnosis
plasma control N = 2; disease N = 5 18
EGFRvIII glioblastoma early diagnosis serum disease N = 30 137
(phospho)Met melanoma early diagnosis/
prognosis
plasma Controls N = 7; stage III N = 24; stage IV
N = 14
23
caveolin-1 melanoma early diagnosis plasma controls N = 58; disease N = 90 20
survivin prostate cancer early diagnosis olasma HD N = 8; BPH N = 20; disease N = 39 25
CD 24 breast cancer early diagnosis serum HD N = 14, disease N = 18 138
EGRF lung cancer diagnosis/
personalized
medicine
serum HD N = 9; disease N = 9 139
miR-21, miR-141, miR-200a, miR-200b,
miR-200c, miR-203, miR-205, miR-214
ovarian cancer early diagnosis/
prognosis
serum HD N = 10; stage I N = 10; stage II N = 10;
stage III N = 20; stage IV N = 10
140
RNU6-1, miR-320, and miR-574-3p glioblastoma early diagnosis serum controls N = 50; disease N = 50 141
TMPRSS2:ERG2 and PCA3 mRNAs prostate cancer early diagnosis urine blinded prospective study N = 30 142
let-7a, miR-1229, miR-1246, miR-150,
miR-21, miR-223, and miR-23a
colorectal cancer early diagnosis serum controls N = 22; disease N = 88 142
miR-21, miR1225-5p gastric cancer prognosis peritoneal
lavage ﬂuid
disease N = 24 28
methylated LINE1 and SOX17 DNA gastric cancer diagnosis gastric juice HD N = 10; disease N = 20 143
CCR6 and HER-2/neu gastric cancer prognosis plasma HD N = 10; disease N = 37 144
miR-151a-5p, miR-30a-3p, miR-200b-5p,
miR-629, miR-100, and miR-154-3p
lung cancer early diagnosis plasma HD N = 10; benign disease N = 10;
malignant disease N = 10
145
TGFB1 and MAGE3/6 ovarian cancer prognosis/therapy
monitoring
plasma HD N = 10; benign disease N = 10;
malignant disease N = 22
146
TYRP2, HSP70, HSC70, VLA-4 melanoma prognosis plasma HD N = 9; stage I N = 2; stage III N = 7;
stage IV N = 18
23
miR-21 human esophageal
cell carcinoma
prognosis serum HD N = 41; disease N = 51 147
KRAS pancreatic cancer personalized
medicine
serum HD N = 2; disease N = 2 148
BRAFV600E, EGFR lung cancer,
melanoma
personalized
medicine
plasma in vivo model N = 8 96
Glypican-1 pancreatic cancer early diagnosis serum HD N = 100; disease N = 190 21
Glypican-1 breast cancer early diagnosis serum HD N = 100; disease N = 32 21
Hsp60 colon cancer early diagnosis/
follow up
plasma controls N = 40; disease N = 57 Cappello
MMP-9, DKP4, EMMPRIN, PODXL renal cell
carcinoma
biomarker
discovery
urine controls N = 23; RCC N = 29 149
EDIL-3/Del1 bladder cancer diagnostic/
prognostic?
urine controls N = 12; patients N = 12 150
Presence: LASS2, GALNT1
bladder cancer diagnosis urine controls N = 11; patients N = 8 151
Absence: ARHGEF39 and FOXO3
TACSTD2 bladder cancer diagnosis urine controls N = 29; patients N = 37 152
ITGA3 and ITGB1 metastatic prostate
cancer
detection urine patients with BPH (N = 5), PCa (N = 5),
and metastatic PCa (N = 3)
153
miR-34a prostate cancer response to
treatment
urine controls N = 36; patients N > 100 (diﬀerent
disease stage)
154
TM256, ADIRF, LAMTOR1 and others. prostate cancer diagnosis/follow
up
urine controls N = 15; prostate cancer N = 16 155
AGR2 splice variants prostate cancer screening/early
diagnosis
urine BPH N = 15; prostate cancer N = 24 156
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207 Peritoneal lavage and gastric juice, for example, may represent
208 promising, noninvasive, and informative sources for gastric
209 cancer diagnosis and/or follow up.28
210 Bronchoalveolar lavage (BALF) is an excellent bioresource
211 for studying lung disorders, including cancer. Bronchoalveolar
212 lavage contains EVs with the morphology, density range, and
213 cargo with diﬀerent size and vesicular forms compared to that
214 of lung surfactant aggregates. In humans, EVs recovered from
215 BALF of healthy individuals were shown to contain major
216 histocompatibility complex (MHC) molecules that may
217 regulate the local immune defense.29 In sarcoidosis, however,
218 the quantity of EVs is increased and they present a relatively
219 greater quantity of MHC class I and class II molecules, as well as
220 other bioactive molecules, such as neuregulin-1. Furthermore,
221 they can activate autologous cells to produce inﬂammatory
222 cytokines.30 In asthma, BALF EVs exhibit particular microRNA
223 (miRNA) proﬁles31 and carry the biosynthetic machinery for
224 leukotriene biosynthesis. Diﬀerent miRNA contents were found
225 in BALF from non-small-cell lung cancer compared to that from
226 plasma.32
227 Extracellular vesicles have also been isolated from nasal lavage
228 ﬂuid and can be used for studying upper airway diseases.33
229 Urinary EVs have also gained much attention as a source of
230 biomarkers, as urine can be collected noninvasively in large
231 amounts, and the isolated EVs are as stable as those from other
232 bioﬂuids. Urine contains highly heterogeneous populations of
233 EVs that are released by the epithelial cells of the genitourinary
234 system,34,35 and the molecular proﬁles of urinary EVs seem to
235 directly reﬂect the pathophysiological state of this system.
236 Therefore, EV-based diagnosis could represent an alternative to
237 current diagnostics, which, for many diseases of the genito-
238 urinary system (kidney, bladder, prostate), rely on poorly
239 predictive, relatively inaccurate biomarkers and/or on biopsy,
240 which is associated with patient morbidity. Recently described
241 isolation, puriﬁcation,36 and analytical strategies for urinary EVs
242 facilitate their in-depth molecular characterization in research
243 settings37,38 and also in hospital settings.39 During pathogenesis,
244 the released EVs are subjected to disease-speciﬁc alterations
245 that can be detected by in-depth proteomic, transcriptomic
246 miRNA analyses or by metabolomics studies35 to reveal the
247 disease-speciﬁc markers that may be validated in preclinical and
248 clinical diagnostic platforms. Notably, studies of the molecular
249 composition of urinary EVs have not been restricted to cancer.
250 Extracellular vesicles may also provide a reliable source of
251 molecules to help understand the metabolic and physiologic
252 state of the urinary tract, providing suitable biomarkers for
253 diseases such as kidney injury, gromerulonephritis, lupus
254 nephritis, diabetic nephropathy, thin basement membrane
255 nephropathy, polycystic kidney disease, and/or ﬁbrosis.35
256 Neurodegenerative Diseases. Extracellular vesicles have
257 been implicated in various neurodegenerative diseases including
258 Alzheimer’s disease (AD), Parkinson’s, and amyotrophic lateral
259 sclerosis. Central nervous system resident neural and non-neural
260 cells all release EVs that can be detected in biological ﬂuids,
261 thus constituting a potentially beneﬁcial source of information.
262 In recent years, several groups have investigated EVs in blood
263 and cerebrospinal ﬂuid (CSF) during neurological diseases.40
264 In several cases, EV analysis is progressing to the clinic despite
265 numerous technological limitations. Among stroke victims,
266 several studies have reported that endothelium and platelets
267 under stress conditions release EVs, whose increase in plasma is
268 proportional to ischemic brain volume.41 In neurodegenerative
269 disorders, the release of neurotoxic protein aggregates in
270association with EVs has been reported,42 and further
271investigations have explored the roles of EVs in the pathogenesis
272of these diseases.43 In fact, an interesting feature of neuro-
273degenerative diseases is that they are characterized by the
274deposition of certain misfolded proteins into amyloid/amyloid-
275like aggregates in distinct regions of the brains. The misfolded
276versions of the proteins are suggested to be the primary culprits
277in the pathogenesis of AD, for instance. Amyloid proteins are,
278in fact, released in association with EVs, fully in agreement with
279the intracellular pathways of amyloid-associated proteins. Both
280immunoelectron microscopy and density gradient separation of
281EVs demonstrate that they contain Aβ peptides, suggesting that
282cells released some of the Aβ peptides in association with EVs,
283which can enable further deposition of peptides into amyloid
284plaques or even facilitate long-range transport. Evidence that
285EVs can participate in the formation of amyloid plaques came
286from the observation that EVs contain many pro-amyloidogenic
287lipids such as cholesterol, gangliosides, and sphingolipids,
288further supporting the hypothesis that they may participate in
289amyloid formation. While many of the underlying studies
290indicate detrimental roles of EVs in promoting amyloids, there is
291some controversy in this regard, as EVs have also been pro-
292posed to have a protective role by aiding in the clearance of
293amyloids.44,45 Extracellular vesicles detected in the CSF are also
294suggested to be a potential source of biomarkers for patients
295with dementia.46 Similarly, in patients aﬀected by neuro-
296inﬂammatory diseases such as multiple sclerosis, CSF EVs
297have been proposed as biomarkers for microglia activation, with
298the possibility of revealing the activation type (i.e., protective or
299detrimental), along with disease progression.47 Finally, seminal
300work has shown that glioblastoma EVs can be detected in
301plasma and reﬂect the corresponding brain tumor volume and
302its response to treatment, which is an extraordinary potential
303advancement over invasive brain biopsies or repeated imaging of
304the brain.48 These studies suggest that further investigations into
305the use of EVs as biomarkers are highly warranted for a series of
306neurological diseases.
307Infectious Diseases. The deﬁnition of the role of EVs in
308the context of infection is still developing, as viruses, bacteria,
309fungi, protozoa, and helminths all secrete forms of EVs,
310and even prions have been detected in EVs.49,50 Clinically
311important pathogens like HIV-1 and hepatitis C and A viruses
312use EVs either to alter the host cell or to transport themselves
313to host cells. Infected cells can, in turn, release EVs that contain
314pathogen-associated molecular patterns (PAMPs) to stimulate
315the immune response.51 On the contrary, infectious agents can
316use EVs to spread infection, facilitating movement of infectious
317materials, and to evade the host immune system response.52
318The Leishmania infantum parasite cultivation strategy used
319to accumulate exogenous antigens dramatically inﬂuences the
320composition of the recovered exoproteome, where an enrich-
321ment of proteins that are known to be essential for infection,
322such as GP63 or EF1, was observed.53 The ﬁrst in vivo demon-
323stration of EV secretion by a pathogen was reported in sand
324ﬂies infected with Leishmania major.54 In this study, parasite
325EVs were coegested with the parasite during the insect’s bite,
326inﬂuencing the host’s infectious process and exacerbating
327the disease symptoms. Thus, EVs have been proposed as
328relevant candidates to add to the repertoire of virulence factors
329associated with vector-transmitted infections.54 Thus, there is
330great potential for EVs as future biomarkers for infectious
331diseases of diﬀerent etiologies, including viral, bacterial, and
332 pparasitic diseases.4
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333 Autoimmune and Other Diseases. Extracellular vesicles
334 seem to play key roles in autoimmune diseases. Behcet’s disease
335 (BD) is a complex multiorgan chronic inﬂammatory condition
336 of unknown etiology wherein the genetic background and
337 environmental factors are thought to be important contributors
338 to disease pathogenesis.55 In BD patients, plasmapheresis has
339 been shown to induce rapid short-term remission, suggesting
340 that an unidentiﬁed plasma-associated factor could be a trigger
341 of ﬂare-ups.56 These patients were found to have elevated EV
342 numbers in their plasma, and the majority of those EVs were
343 derived from platelets. It has been proposed that a plasma EV
344 number-based stratiﬁcation of BD could more precisely identify
345 inactive and active disease states and so could aid in its
346 pharmacological management.
347 Glycosylation changes of EVs are being considered as disease
348 biomarkers. In addition, other types of molecules, such as
349 glycans, have been shown to be EV-linked biomarkers of
350 diﬀerent diseases, including some inﬂammatory and auto-
351 immune diseases. For example, urinary EVs from patients with
352 classical galactosemia are characterized by complex-type
353 N-linked glycosylation in contrast to healthy subjects whose
354 EV glycosylation was mainly of high-mannose-type.57 Surface
355 glycosylation of urinary EVs was also analyzed in autosomal
356 dominant polycystic kidney disease (ADPKD). Here, lectin
357 microarray analysis revealed that 6 out of 43 diﬀerent lectins
358 have diﬀerent binding intensity to EVs from individuals with
359 ADPKD compared to EVs from healthy subjects.58 All of these
360 ﬁndings demonstrate the biomarker potential of EV glycans and
361 the applicability of high-throughput techniques (such as lectin
362 microarrays) in selecting lectins that can be used as the basis for
363 establishing new diagnostic assays.
364 NANOSIZED EXTRACELLULAR VESICLES AS
365 THERAPEUTIC AGENTS
366 Tumor and Infectious Disease Vaccination. As
367 described above and previously reviewed,4 EVs from diﬀerent
368 cell types exert a variety of diﬀerent physiological functions.
369 Initiated with the observation that B-cell-derived EVs carry
370 functional MHC−peptide complexes on their surface and
371 contain the potential to exert T cell stimulatory functions,59
372 interest was raised in using EVs as immune modulatory agents.
373 After it was shown that EVs derived from dendritic cells (DCs)
374 pulsed with tumor antigens mediated antitumor responses,60
375 limited numbers of preclinical and clinical trials investigated
376 the role of DC-derived EVs as antitumor therapies. So far,
377 two phase I clinical trials have been performed, one in France
378 and one in the United States, to treat melanoma or small-cell
379 lung carcinoma patients, respectively (Table 2).61,62 The trials
380 mainly demonstrated feasibility and safety; a small number of
381 patients beneﬁted from the treatment, resulting in the initiation
382 of a clinical phase II trial in France to treat non-small-cell lung
383 cancer patients.63 Although the later therapy did not induce
384 detectable eﬀector T cell responses, a positive eﬀect on natural
385 killer (NK) cells was observed in some patients.64 Following
386 the same strategy, EVs from DCs pulsed with pathogens of
Extracellular vesicles have been impli-
cated in various neurodegenerative
diseases including Alzheimer’s disease,
Parkinson’s, and amyotrophic lateral
sclerosis.
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387 infectious disease, such as fungi, bacteria, parasitic protozoa, and
388 helminths, might be useful as agents in anti-infectious disease
389 treatment. In fact, proof-of-principle trials have been performed
390 with DC-EVs obtained from Toxoplasma gondii-pulsed DCs.
391 Indeed, such EVs conferred protection against subsequent
392 Toxoplasma infections in preclinical models.65−67 Proof-of-
393 principle vaccination trials have been also performed in
394 preclinical animal models for malaria infection. Here, applica-
395 tion of EVs from infected reticulocytes were found to protect
396 mice from lethal Plasmodium yoelii infections,68 thus reinforcing
397 the use of EVs as a new therapeutic approach against parasitic
398 diseases.
399 In other settings, EVs directly released from pathogens or
400 from pathogen-infected cells have been used to pulse DCs
401 in vitro or for subsequent in vivo vaccination in a number of
402 preclinical models.6,69 In a similar context, outer membrane
403 vesicles (OMVs), which are continuously produced by Gram-
404 negative bacteria by vesiculation of the outer membrane,70 have
405 successfully been used as vaccines.71 For example, an OMV-
406 based vaccine named Bexsero has been generated by Novartis.
407 It eﬃciently protects against Neisseria meningitides infections
408 and is used as a vaccine against serogroup B meningococcal
409 diseases in children.72,73 Extracellular vesicles as vaccines have
410 also been used in antitumor therapy. Speciﬁcally, in a phase I
411 clinical trial performed in China, EVs from ascites ﬂuid from
412 colorectal cancer patients were used as a vaccine to trigger
413 antitumor activities of DCs (Table 2). Feasibility and safety
414 were demonstrated.74 Preclinical and clinical EV-based vaccina-
415 tion trials for antitumor treatment or to ﬁght infectious diseases
416 indicate that this therapeutic concept is safe and feasible. The
417 future will show how this can be translated as nanomedicinal
418 approaches in clinics.
419 Immune Suppressive and Regenerative Therapies.
420 Patient cohorts with a variety of diﬀerent degenerative and
421 inﬂammatory diseases have been treated with somatic stem
422 cells, especially with mesenchymal stem cells (MSC), either to
423 promote regeneration or to suppress inﬂammation.75 Contrary
424 to the original assumption that stem cells integrate into aﬀected
425 tissue to exert their therapeutic function, they instead seem to
426 act in a paracrine rather than in a cellular manner. The results
427 of increasing numbers of studies in preclinical models and a
428 single treatment attempt of a graft versus host disease patient
429 suggest that EVs exert the stem cells’ therapeutic eﬀects.6,76−78
430 Head-to-head comparisons of MSC and MSC-EV applica-
431 tions have been performed in animal models for acute kidney
432 failure79 and ischemic stroke.80 Signiﬁcant diﬀerences were
433 undetected.
434 Thus, it is feasible that, in the future, stem-cell-derived EVs
435 could be used instead of stem cells to treat various diseases.
436 There are several challenges to be addressed before stem-cell-
437 derived EVs can be approved for the treatment of certain
438 diseases, but compared to therapies with stem cells, they provide
439 a variety of advantages. In contrast to cells as non-self-renewing
440 units, EVs lack any endogenous tumor-formation potential.
441 Furthermore, they can be sterilized by ﬁltration through
442 0.22 μm ﬁlters and can be handled, stored, and characterized
443 more easily than cells. However, it has to be considered that
444 any given EV samples may provide heterogeneous mixtures of
445 diﬀerent EV subentities, all containing diﬀerent compositions.
446 For biological activity, heterogeneity may be an important
447 parameter, as EVs may concomitantly convey multiple signals
448 that act synergistically for a deﬁned activity. However, this
449 heterogeneity provides a challenge to the standardization of EV
450preparations. Recent ﬁndings indicate that EVs released from
451stem/progenitor cells promote tissue regeneration by modu-
452lation of gene transcription and induction of epigenetic changes
453in recipient cells and by delivering growth factors,81 but studies
454on the mode of action and identiﬁcation of potentially healing
455molecules carried by EVs are a challenge for the ﬁeld. Rapid
456translation of EV products for therapeutic use is also challenged
457by the lack of standard puriﬁcation and characterization
458methods that can be used in clinical settings.6 However, a
459number of research groups and companies are working on these
460challenges. It is highly likely that stem-cell-derived EVs as well as
461EVs from other cell types (e.g., endothelial cell or regulatory
462T cells82−87) will advance to clinical applications within the next
463few years. Treatments of a range of diseases have been
464considered as potentially proﬁting from EV therapies, including
465autoimmune, chronic, and acute inﬂammatory diseases such as
466rheumatoid arthritis, inﬂammation of connective and vascular
467tissues, autoimmune inﬂammatory disease, intestinal chronic
468inﬂammatory diseases, Crohn’s diseases and ulcerative colitis,
469type 1 diabetes, multiple sclerosis, cystic ﬁbrosis, graft versus host
470disease, as well as diseases associated with acute tissue damage
471such as myocardial infarction, ischemic stroke, acute and chronic
472kidney failure, drug-induced liver injury, hypoxia-induced
473pulmonary hypertension, hind limb ischemia, and perinatal
474asphyxia.6
475Further, within the context of EV research, parasites
476(including helminths) have been shown to produce EVs
477expressing immunomodulatory molecules.50 Such EVs have
478been considered for the treatment of autoimmune disorders.88
479Indeed, recent studies have shown the usefulness of EVs from
480Heligmosomoides polygyrus, a parasitic roundworm, in a rodent
481model of allergy.89
482Drug Delivery. From an applied perspective, synthetic
483lipoproteins have long been considered to be viable nano-
484carriers for targeted delivery of drugs90−93 because numerous
485cancers overexpress light density lipoprotein receptor. The
486most widely exploited drug-delivery platform is based on
487liposomes or lipid-based nanoparticles (LNPs). These nano-
488formulations have been used eﬀectively to encapsulate various
489macromolecular drugs including proteins, chemotherapeutics,
490imaging agents, and diﬀerent species of therapeutic RNAs
491(e.g., small interfering RNA, siRNA). Many of these bind to
492apolipoprotein E (ApoE) in blood and facilitate eﬃcient
493delivery to the liver.92 Despite being eﬀective, the main limita-
494tions with current nanocarriers based on LNPs are potential
495toxicity/immunogenecity and limited ability to penetrate organs
496and tissues outside the reticuloendothelial system (RES). Hence,
497EVs have emerged as candidates for drug delivery. Several
498reports have indicated the high delivery potential of EVs, such as
499paclitaxel in autologous prostate cancer EVs,93 in particular, in
500relation to endogenous protein and miRNA transfer.94
501Furthermore, they can contain gDNA.95,96 Extracellular vesicles
502have also successfully been used to deliver exogenous drugs such
503as small molecules, miRNAs, and siRNAs.97 Recently, it was
504demonstrated that even an exogenous protein (catalase) can be
505loaded into EVs and subsequently confer neuroprotection in
506models of Parkinson’s disease.98
507By engineering EVs to display targeting moieties, tissues
508beyond the RES are amenable to targeting even after systemic
509delivery.99,100 Although EVs hold true potential as drug-delivery
510platforms, we note that the eﬃcacy of loading of the lipophilic
511small drugs is good,94 but in the case of siRNA, it is very low.101
512Similarly, in the case of endogenous miRNA transfer with EVs,
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513 caution has to be taken, as the majority of extracellular RNA is
514 not associated with EVs.102 Thus, strategies are needed that can
515 increase exogenous drug loading or methods of manipulating
516 producer cells that permit selective loading of proteins or RNA
517 into EVs. Examples where loading of drugs (in addition to the
518 self-assembly of lipophilic drugs) could be achieved include
519 the use of extruded vesicles from cells as well as synthetic
520 EVs.103−105 However, it remains to be shown whether such
521 systems are equally eﬀective and safe as naturally secreted and
522 puriﬁed EVs. In this context, it is interesting to note that
523 exosomes released from melanocytes and melanoma cells
524 were recently found to interact physically with ApoE-associated
525 lipoparticles, maybe indicating that each of the diﬀerent
526 nanomessengers can be combined to make use of each of
527 their advantages as a drug-delivery tool.106
528 Nanoparticle PEGylation (PEG is a coiled polymer of
529 repeating ethylene ether units with dynamic conformations) is
530 the current standard for stealth in nanoparticle drug delivery.
531 However, potential immunological response and absence of
532 active targeting prevent its widespread use.107 PEGylated nano-
533 particles rely on the enhanced permeability and retention (EPR)
534 eﬀect for tumor targeting, which is absent if primary tumors
535 or metastases are smaller than 100 mm3.108 Bioconjugation
536 approaches of PEGylated nanoparticles with targeting ligands
537 to self-organize into some useful conformation are ambiguous
538 because of denaturation of proteins during the conjugation
539 process and the overall diﬃculty of duplicating biological
540 complexity on the nanoscale.109 These disadvantages are largely
541 absent when functionalizing PLGA (poly(lactic-co-glycolic
542 acid)), gold, or silicon nanoparticles with cellular plasma
543 membranes. This has already been successfully demonstrated
544 with cancer cell membranes to induce an immune response
545 (i.e., as a vaccination)110 and by leukocyte and erythrocyte
546 membranes to enhance circulation times (i.e., by avoiding
547 immune uptake)109,111 and increasing cancer cell speciﬁcity.111
548 These hybrids possess the ease-of-use and ﬂexibility of synthetic
549 materials, as well as the functionality and complexity of natural
550 materials. Thus, EV-sized, cell-membrane-camouﬂaged nano-
551 particles are a delivery strategy with the potential to improve the
552 therapeutic eﬃcacy of the treatment of a variety of diseases.
553 Extracellular Vesicles in Milk. According to epidemio-
554 logical analysis, human milk is better than artiﬁcial infant
555 formula in allowing appropriate metabolic programming and
556 protecting the baby against conditions such as type 2 diabetes,
557 obesity, and hypertension in later life. Puriﬁcation of EVs from
p 558 breast milk has been described.112,113
559 Breast milk is rich in many bioactive molecules all sent to the
560 baby in diﬀerent packaging (e.g., exfoliated cells, microvesicles,
561 fat globules). Finding and using natural sources of EVs loaded
562 with bioactive miRNA from mammals will require extensive
563 eﬀort in purifying and characterizing EVs both from milk and
564 from digestive ﬂuids of the baby. The design of artiﬁcial nano-
565 particles for breast milk supplementation remains unresolved.
566 Other Therapeutic Implications. In discussing EVs’
567 potential for therapy, a number of glycobiological aspects of
568EVs are worth mentioning. First, from a fundamental point of
569view, glycans (as other molecules) are speciﬁcally enriched or
570excluded from EVs. The fact that A/B blood group antigens
571are excluded from EVs compared to the plasma membrane is
572what enables EVs to be used therapeutically.114 Second, from a
573technological point of view, speciﬁc targeting of EVs loaded
574with therapeutics may be accomplished by displaying peptides
575on their surfaces. An associated issue is proteolytical degradation
576of such peptides in circulation, but this can be prevented by
577introducing a glycosylation motif at speciﬁc positions, without
578inﬂuencing protein−target interactions.115 Third, for applica-
579tions, speciﬁc glyco-proﬁles of EVs related to several diseases
580were detected by lectins, and new adjuvant cancer therapy
581strategies employing lectins to remove circulating cancer-derived
582EVs selectively have been proposed.116
583Extracellular Vesicles in Cosmetics. Recent studies have
584highlighted roles for EVs in the skin. Maintenance of skin
585pigmentation, which is required for skin color and for photo-
586protection against harmful UV radiation, is the consequence of
587tight intercellular communication between keratinocytes and
588melanocytes. In an academic−industrial collaboration between
589the Raposo group and Clarins Laboratories, it was shown that
590human primary keratinocytes secrete EVs that are targeted to
591melanocytes to modulate pigmentation. Extracellular vesicles
592are key actors in skin pigmentation, enhancing melanin synthesis
593by increasing the expression and activity of melanosomal
594proteins.117 These eﬀects are connected to particular miRNA
595compositions. Furthermore, the function of keratinocyte-derived
596EVs has been demonstrated to be photo-type-dependent and is
597modulated by UVB. This study not only uncovers an important
598physiological function for EVs in our understanding of how
599pigmentation is regulated by intercellular communication but
600also opens new avenues for technological development. For
601example, based on these ﬁndings, Clarins recently launched a
602new product that, likely by acting on the composition of EVs,
603inhibits overproduction of melanin (“Seŕum Mission Perfection
604de Clarins”).
605PRECLINICAL DATA SUPPORT A GREAT FUTURE
606FOR NANOSIZED EXTRACELLULAR VESICLES
607IN NANOMEDICINE
608Based on the clinical evidence (outlined above) showing that
609EVs may be exploited as either disease biomarkers or therapeutic
610tools, it is conceivable that EVs may represent key players in the
611future of nanomedicine and, in particular, in the ﬁeld aimed at
612deﬁning the most biomimetic approach in nanomedicine. The
613presence of EVs in the plasma of both healthy individuals and
614those with various diseases suggests that EVs may serve as
615vectors for transferring information to tissues and organs far from
616their places of production, that is, acting in a paracrine manner.
617These actions indicate that EVs may well diﬀuse normal,
618abnormal, or aberrant messages to cells both close to their
619origins and at distances. This, in turn, suggests that EVs may
620play key roles as nanodevices belonging to integrated networks
621involved in multiple pathophysiologies. Our current under-
622standing is that EVs are key regulators of normal functions of
623the body.4
624It is conceivable that in the near future nanosized EVs may
625be helpful in the screening and diagnosis of viral diseases.
626In fact, we have evidence that EVs are natural delivery systems
627for a variety of viruses including EBV, HCV, HIV, coxsackie
628virus B1, and hepatitis A.118−124 Moreover, prion proteins
629are shuttled by nanovesicles, although only preclinical data are
EV-sized, cell-membrane-camouﬂaged
nanoparticles are a delivery strategy
with the potential to improve the
therapeutic eﬃcacy of the treatment of
a variety of diseases.
ACS Nano Perspective
DOI: 10.1021/acsnano.5b08015
ACS Nano XXXX, XXX, XXX−XXX
H
630 available to date.125−129 The data strongly suggest that
631 EV-based tests will be included in new screening approaches
632 for transmissible diseases, for example, in blood donors.
633 Preclinical data also support the use of EVs as the most
634 biomimetic nanovectors for a variety of molecules, including
635 proteins, nucleic acids, and chemicals. Nanosized EV-encapsulated
636 curcumin, delivered by the intranasal route, is eﬃcient in
637 preventing brain inﬂammation and is more eﬀective than
638 curcumin alone.130 Moreover, EVs released by human tumor
639 cells or human tumors treated with cisplatin contain cisplatin in
640 its active/native form.131 The future of the clinical use of EVs
641 depends on a high level of networking between researchers
642 involved in the ﬁeld and a strategic approach on how to guide
643 future research. A level of consensus was recently achieved by the
644 International Society for Extracellular Vesicles (ISEV), although it
645 has not yet been fully implemented in clinical studies.6,132,133
646 Funded by Europe’s Horizon 2020 program, a consortium of
647 academic, clinical, and industry partners with a common interest
648 in EVs has been established. This cooperation in science and
649 technology, entitled the European Network on Microvesicles
650 and Exosomes in Health and Disease (ME-HaD), includes EV
651 researchers from 27 European countries and allied groups from
652 the United States and Australia. The aim of ME-HaD is to foster
653 multidisciplinary approaches to research in this ﬁeld, including
654 the theranostic relevance of EVs, with the ultimate goal of
655 exploiting EVs for clinical applications, which is achievable only
656 through coordinated eﬀorts and valorization. Guided, mentored,
657 and trained by more experienced EV researchers within
658 ME-HaD, this consortium currently includes membership of
659 more than 250 early stage researchers, who will hopefully be the
660 future leaders in the ﬁeld of EV research and application.
661 THE FUTURE OF EXTRACELLULAR VESICLES IN
662 NANOMEDICINE AND INDUSTRY INVESTMENT
663 The life science market is remarkably conservative, relative
664 to the extremely dynamic EV market. For instance, ultra-
665 centrifugation is still the gold standard for EV isolation, used
666 by ∼60% of researchers in the ﬁeld. The acceptance of novel
667 commercial tools is slow. The pharma industry, however, is
668 open to EV-based solutions in companion diagnostics and
669 personalized medicine if they are reliable and speciﬁc for EVs.
670 Thus, EV analysis will likely enable rapid in vitro diagnostic or
671 laboratory-developed/exoteric tests for hospitals or centralized
672 laboratories and will also be tools for quality control of produc-
673 tion processes and surrogate markers for the development of
674 novel therapies.
675 1. In order to surmount regulatory hurdles (which are
676 diverse and rapidly evolving in the biggest markets, such as the
677 United States, the European Union, and Asia) and both market
678 and cultural insertion, extensive clinical validation and techno-
679 logy beta testing is needed. This calls for time, money, and
680 collaborative research eﬀorts including multiple stakeholders
681 so as to produce deﬁnitive evidence that EV marker assays
682 outperform and/or complement conventional diagnostics, thus
683 leading to a broad acceptance from clinicians and patients.
684 2. The technological readiness level of EV analysis might
685 not be suﬃciently robust. Fabrication of novel materials and
686 sophisticated devices (microﬂuidic chips or speciﬁc sensors)
687 has produced some exciting proof-of-concept applications
688 of advanced technologies. These have limited application in
689 routine laboratory practice, however, due to cost or because
690 they still are not guaranteed to work in “all hands”, according
691 to their inventors. On the other hand, we have convincing
692evidence of EV detection and analysis using cost-eﬀective and
693familiar formats of assays that are compatible with oﬀ-the-shelf
694laboratory equipment such as plate readers or polymerase chain
695reaction (PCR) cyclers.20,134
696Extensive developments in the ﬁeld of EVs, in particular, the
697promising preliminary results from using EVs, therapeutically
698and as diagnostics markers, has resulted in a number of start-ups
699that have initiated commercialization of these achievements.
700Big and small pharmaceutical companies have already taken
701ﬁrst steps in evaluating development, costs of the investments,
702and registration and commercialization strategies. Promising
703results and demands for new therapeutic EV development will,
704undoubtedly, stimulate pharmaceutical industry interest in the
705production of therapeutic EVs at larger scales.
706The active participation of the pharmaceutical industry
707should support the development of the ﬁeld of EVs. Large
708companies, with a high volume of starting material and the
709availability of analytical tools, will accelerate development of the
710detection and characterization of EVs by both the evaluation
711of commonly used techniques and the development of new
712techniques. In addition, the pharmaceutical industry’s high
713demands for quality regulation will accelerate standardization
714of EV sample collection, isolation, and analysis methods, which
715are highly desirable outcomes.
716CONCLUSIONS AND PROSPECTS
717Nanosized EVs, which may both contain disease biomarkers
718and/or be the vectors of potential therapeutic molecules, thus
719represent the ideal theranostic approach. This new multi-
720disciplinary ﬁeld focuses on building nanosystems for future
721joint applications of diagnosis and therapy. The theranostic
722“all-in-one approach” has great potential in the ﬁeld of
723personalized medicine, as it enables the detection and
724monitoring of a disease in individual patients, possibly in early
725clinical stages, as well as targeted drug delivery at the site of the
726disease. Here, we have included data dealing with clinical studies
727and provided evidence that EVs are currently used in clinical
728research as biomarkers of disease and as therapeutic tools. Thus,
729this Perspective emphasizes the evidence that natural nanosized
730EVs are critical to the future of nanomedicine.
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